03 November 1997
Long-term effects of vaccination against hepatitis virus B infection in children with neoplastic disease
Jan Styczyński, Mariusz Wysocki, Sylwia Kołtan, Andrzej Kurylak, Anna Balcar-BorońMed Sci Monit 1997; 3(6): CR864-868 :: ID: 501816
Abstract
The purpose of the study was to assess the durability of humoral immunity in children with neoplastic disease 2.5 years after vaccination against hepatitis B virus. The study included 53 children divided into 3 groups, according to the method of passive-active prophylaxis. In group A first came passive prophylaxis during intensive chemotherapy, followed by the vaccination during supportive treatment; in group B children were vaccinated from the very beginning of chemotherapy with simultaneous administration of 2 doses of anti-HBs immunoglobulin; in group C patients received vaccination only after the completion of chemotherapy. Engerix-B vaccine was used for vaccination, and was administered in double doses, in regimen 0-1-2-8 months. Humoral response was evaluated in the 6th and 30th month following the fourth vaccination. After the vaccination cycle was completed, seroprotection was obtained in 66.7% of children in group A, 81.3% in group B and 100% in group C. Two and a half years after the termination of vaccination, all patients with primary seroconversion still possessed anti-HBs antibodies, while in two children the anti-HBs antibodies appeared after the discontinuation of chemotherapy. Anti-HBs antibody level increased in 45.3% of patients. Among patients who received the last dose of vaccine upon the completion of chemotherapy, as compared to those who received the last dose of vaccine during chemotherapy, we found a higher percentage of seroconversion to anti-HBs³10 IU/l (p<0.01) and higher mean arithmetic (p<0.05) in the 30th month after completion of vaccination. Geometric mean value of protective level of antibodies was in these patients more than two times higher. Long-term effects of vaccination in children with neoplastic disease reveal improvement of humoral response after the discontinuation of chemotherapy. More permanent results were obtained in children who received the last dose of the vaccine upon the completion of treatment.
Keywords: HBV infection, Vaccination, antibodies maintenance, children neoplasm
Editorial
01 March 2024 : Editorial
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-ThalassemiaDOI: 10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
In Press
18 Mar 2024 : Clinical Research
Sexual Dysfunction in Women After Tibial Fracture: A Retrospective Comparative StudyMed Sci Monit In Press; DOI: 10.12659/MSM.944136
21 Feb 2024 : Clinical Research
Potential Value of HSP90α in Prognosis of Triple-Negative Breast CancerMed Sci Monit In Press; DOI: 10.12659/MSM.943049
22 Feb 2024 : Review article
Differentiation of Native Vertebral Osteomyelitis: A Comprehensive Review of Imaging Techniques and Future ...Med Sci Monit In Press; DOI: 10.12659/MSM.943168
23 Feb 2024 : Clinical Research
A Study of 60 Patients with Low Back Pain to Compare Outcomes Following Magnetotherapy, Ultrasound, Laser, ...Med Sci Monit In Press; DOI: 10.12659/MSM.943732
Most Viewed Current Articles
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952